HRSA Issues Final 340B Orphan Drug Exclusion Rule: Agency’s Narrow Interpretation of Statutory Prohibition Puts Compliance Responsibility in the Hands of Covered Entities


On July 23, 2013, the Health Resources and Services Administration (HRSA) issued a final rule clarifying the orphan drug exclusion for certain covered entities created by the Affordable Care Act (ACA) (“Final Rule”). The Final Rule is available here, has an effective date of October 1, 2013, and applies prospectively from that date. The text of the new 340B regulations created by the Final Rule, 42 C.F.R. Part 10, appears at the end of this Client Alert.

In short, the Final Rule permits the new categories of covered entities access to 340B pricing for orphan drugs based on the covered entity’s intended use. In one sense, the Agency rule is surprising given statutory language that would appear to limit these covered entities’ access to the 340B program’s deeply discounted pricing for orphan drugs without regard to the condition the drug will be used to treat. Treatment-specific considerations have never been part of access to 340B discounts: HRSA’s new interpretation of the 340B statute is a watershed moment in the history of the 340B Program. Further, HRSA has crafted a rule that puts determination of eligibility to purchase orphan drugs at 340B prices squarely in the hands of the affected covered entities. Drug manufacturers are not afforded any opportunity at the point-of purchase to gauge the validity of the claim for discounts, and are given little authority after the fact to check the covered entity records that are the sole mechanism of ensuring compliance with the orphan drug exclusion rule, short of audit or referral to HRSA for investigation.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:


King & Spalding on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.